Drug Trial Radar · NCT02872714
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
263
Actual
Start
Jan 12, 2017
Primary completion
Feb 1, 2022
Study completion Feb 1, 2022
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Aug 19, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.
Conditions
- UC (Urothelial Cancer)
Interventions
pemigatinibDrug
Pemigatinib once a day by mouth for 2 consecutive weeks and 1 week off therapy.
pemigatinibDrug
Pemigatinib once a day by mouth continuously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD RegimenTime frame: up to 1138 days
Locations
96 sites in 11 countries. Site status is shown where the registry gives one.
Arizona Oncology Associates (Wilmot)
Tucson, Arizona
Sharp Memorial Hospital
San Diego, California
UCSF Helen Diller Family Comprehensive Care Center
San Francisco, California
Rocky Mountain Cancer Centers
Boulder, Colorado
Calaway-Young Cancer Center at Valley View Hospital
Glenwood Springs, Colorado
Mount Sinai Medical Center
Miami Beach, Florida
Florida Hospital Cancer Institute
Orlando, Florida
Emory University School of Medicine
Atlanta, Georgia
University of Maryland, Greenebaum Cancer Center
Baltimore, Maryland
Lahey Clinic Inc. - PARENT ACCOUNT
Burlington, Massachusetts
Minnesota Oncology Hematology, P.A.
Woodbury, Minnesota
GU Research Network
Omaha, Nebraska
TRIO - Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
New York Oncology Hematology, P.C.
Albany, New York
Northwell Cancer Institute
New Hyde Park, New York
University of Rochester
Rochester, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Oncology Hematology Care, Inc.
Cincinnati, Ohio
Oregon Health & Science University
Portland, Oregon
Compass Oncology the Northwest Cancer Specialists
Tualatin, Oregon
St. Luke's Hospital
Bethlehem, Pennsylvania
VA Pittsburgh Healthcare System
Pittsburgh, Pennsylvania
Carolina Urologic Research Center
Myrtle Beach, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Texas Oncology, P.A. - Austin
Austin, Texas
Texas Oncology - Baylor Charles A. Sammons
Dallas, Texas
Texas Oncology
Houston, Texas
Texas Oncology, P.A. - Sherman
Sherman, Texas
Baylor Scott & White Health
Temple, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
Virginia Oncology Associates - Hampton
Norfolk, Virginia
Northwest Medical Specialties, PLLC
Tacoma, Washington
University of Wisconsic Hospital and Clinic
Madison, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin
UZ Antwerpen
Edegem, Belgium
AZ Sint-Lucas - Campus Sint-Lucas
Ghent, Belgium
AZ Groeninge Campus Loofstraat
Kortrijk, Belgium
AZ Delta
Roeselare, Belgium
Rigshospitalet
Copenhagen, Denmark
Groupe Hospitalier Pitie-Salpetriere
Paris, France
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.